Galderma Adds Two Director Candidates as Its CFO Departs

By Daniel Okafor

Galderma seeks two new directors and an 11-seat board on December 3, 2026. The virtual extraordinary general meeting starts at 14:00 CET. Shareholders will consider electing Rosalind Brewer and Petra Rumpf.

Luigi La Corte, the company’s chief financial officer, has decided to leave for what Galderma calls “a significant new opportunity.” The Zug, Switzerland-based company made the announcement as an ad hoc disclosure under Article 53 LR. Those decisions put board oversight and financial succession at the center of its next phase.

Who is leaving, and whom may shareholders add?

Galderma said La Corte will fulfill his CFO responsibilities during the transition, supporting business continuity and a smooth handover. La Corte will remain responsible for the CFO role during the transition, yet the company has not disclosed his final departure date or named a successor. Galderma will communicate succession arrangements and the transition timeline later.

Flemming Ørskov, M.D., MPH, Galderma’s chief executive officer, thanked La Corte for his contributions and his commitment to a smooth transition. “We remain focused on executing our Integrated Dermatology Strategy and delivering against our priorities,” Ørskov said.

Takeaway: The finance transition is underway, but shareholders still lack a named successor or firm departure date.

What will the December 3 vote change?

The proposals on the extraordinary general meeting agenda include:

• Increasing the maximum Board size from 10 to 11 members, a one-seat expansion.
• Electing Rosalind Brewer and Petra Rumpf as directors until the completion of the next Annual General Meeting.
• Holding a separate election for Brewer to join the Compensation Committee.

Sherilyn McCoy will leave the board after seven years of service because of conflicting obligations. Her departure creates the context for the proposed changes in board composition.

The governance package combines one departing director, two proposed additions, one additional permitted seat and a separate vote on committee membership at the virtual meeting.

Galderma says Brewer and Rumpf bring extensive leadership and governance experience. Their listed backgrounds span consumer-facing businesses, healthcare, medtech and life sciences.

Takeaway: One vote would refresh the board, add one permitted seat and place Brewer on the Compensation Committee.

How does this fit Galderma’s strategy?

Ørskov tied the appointments to Galderma’s broader governance and growth plans. He cited the company’s recent inclusion in the Swiss Market Index (SMI) and said the two candidates would add expertise and perspectives to support long-term ambitions.

Galderma describes itself as a pure-play dermatology category leader with a science-based portfolio of premium brands and services. The portfolio spans Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology, three businesses the company presents as parts of a fast-growing market.

Across those businesses, Galderma says its ambition is to become the “undisputed dermatology powerhouse,” a corporate aim rather than a clinical finding or regulatory milestone. The company operates in approximately 90 countries and has focused on the skin since its foundation in 1981. It describes the skin as the human body’s largest organ and says it works with healthcare professionals to meet consumer and patient needs. In its corporate description, Galderma says the partnership is intended to support superior outcomes. No trial data accompany that statement.

Takeaway: The board additions are meant to support injectables, dermatological skincare and therapeutic dermatology.

What remains unresolved?

The announcement does not name La Corte’s successor, specify his final day, detail his new role or announce changes to products, development programs or market operations. Galderma has posted the 2026 EGM agenda and invitation for review.

The corporate disclosure does not report clinical trial results, treatment effects, new indications or pricing changes. It instead centers on governance capacity, committee oversight and succession planning.

Takeaway: The next checkpoints are the December 3 vote and Galderma’s later update on succession and timing.